GlobeNewswire Inc | Nov 3, 2021 07:00AM EDT

November 03, 2021

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences:

-- Credit Suisse 30th Annual Virtual Healthcare ConferenceThursday, November 11, 2021 at 4:20pm ET

-- Stifel Virtual Healthcare ConferenceWednesday, November 17, 2021 at 11:20am ET

-- Piper Sandler 33rd Annual Virtual Healthcare ConferenceTuesday, November 30, 2021. Webcast available beginning Monday, November 22, 2021 at 10:00am ET

Live audio webcasts will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Companys website for 30 days.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrums proprietary product engine, FulcrumSeek, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Fulcrum has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.

Please visit www.fulcrumtx.com.

Contact:Naomi AokiSr. Vice President, Corporate Communications and Investor Relations naoki@fulcrumtx.com